Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


U.K. Looks to 'Rebalance' Economy; Tech University Would Play Role

24 January 2012

Professors Stephen Caddick, Vice-Provost (Enterprise) and Stephen Moss (UCL Institute of Ophthalmology) comment on David Willett’s proposals for a “new type of university with a focus on science and technology and on postgraduates”.